IMUNON IMNN-001 Ovarian Cancer Breakthrough

IMUNON, a clinical-stage biotechnology company, announced highly positive results from its Phase 2 OVATION 2 Study of IMNN-001, an investigational DNA-mediated immunotherapy for newly diagnosed advanced ovarian cancer. The study showed a median increase of 13 months in overall survival and 3 months in progression-free survival for patients treated with IMNN-001 plus standard-of-care chemotherapy, compared to standard-of-care alone. These unprecedented results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Gynaecological Cancers Congress 2025, and simultaneously published in the peer-reviewed journal Society of Gynecologic Oncology. Following these encouraging findings and alignment with the United States — Food and Drug Administration, IMUNON has initiated its pivotal Phase 3 OVATION 3 Study, with Washington University School of Medicine as the first trial site. IMNN-001, based on IMUNON's TheraPlas® technology, works by inducing IL-12 and other anti-cancer immune cytokines at the tumor site, showing a favorable safety profile. This development represents a significant advancement in the treatment of advanced ovarian cancer, a disease with high recurrence rates and poor survival outcomes.